Citations

Clear

27 citation(s) found for "Jahangir, Arshad".

Catheter Ablation for Atrial Fibrillation in Patients With Obesity
Cha, Yong‐Mei , Friedman, Paul A. , Asirvatham, Samuel J. , Shen, Win-Kuang, Munger, Thomas M. , Rea, Robert F., Brady, Peter A. , Monahan, Kristi H. , Hodge, David O. , Meverden, Ryan A., Hammill, Stephen C., Packer, Douglas L. , Jahangir, Arshad , Gersh, Bernard J. , Asirvatham, Samuel J

Mayo Clinic

Circulation | May 13, 2008 | Volume: 117 | Issue: 20 | Pages: 2583-2590

10.1161/circulationaha.107.716712 | PMID 18474813 Get It

Background— Obesity is a risk factor for atrial fibrillation and other cardiovascular conditions. Our objective was to determine whether catheter-based ablation effectively treated atrial fibrillation in obese patients. Methods and Results— Five hundred twenty-three consecutive patients with symptomatic, medication-refractory atrial fibrillation underwent catheter ablation. Patients were grouped by body mass index (lean, <25 kg/m 2 ; overweight, 25 to 29.9 kg/m 2 ; obese, ≥30 kg/m 2 ). Outcome and quality of life were measured with a general health survey (Medical Outcomes Study 36-item Short-Form General Health Survey [SF-36]); patients were assessed before ablation and at 3 and 12 months after the procedure. Two hundred twenty-eight study patients (44%) were overweight, and 201 (38%) were obese. Twelve months after curative ablation, 72% of patients were free of atrial fibrillation without the use of antiarrhythmic agents; 84% were arrhythmia free when those receiving medication were included. Atrial fibrillation was eliminated in 75%, 72%, and 70% of the lean, overweight, and obese patients, respectively, at 12 months ( P =0.41, trend test). SF-36 scores were lower for patients with higher body mass index ( P <0.05) at baseline. SF-36 scores improved in every functional domain for all body mass index groups after ablation. The mean SF-36 total physical score increased from 59±20 at baseline to 77±19 in 12 months ( P <0.001). The total mental health score improved from 66±18 to 79±16 in 12 months ( P <0.001). Conclusions— Catheter ablation of atrial fibrillation was effective in obese patients. Coexistence of atrial fibrillation and obesity indicated lower SF-36 scores, but the improvement in quality of life was consistent across all body mass index categories.
Cardiac Resynchronization by Restoration of Native Ventricular Activation
Sagar, Sandeep , Espinosa, Raúl E. , Louwagie, Curtis R., Olson, Lyle J. , Jahangir, Arshad

Mayo Clinic

Circulation | April 22, 2008 | Volume: 117 | Issue: 16 | Pages: 2160-2161

10.1161/circulationaha.107.718650 | PMID 18427146 Get It

Long-Term Progression and Outcomes With Aging in Patients With Lone Atrial Fibrillation
Friedman, Paul A. , Trusty, Jane M., Hodge, David O. , Kopecky, Stephen L. , Packer, Douglas L. , Hammill, Stephen C., Shen, Win-Kuang, Jahangir, Arshad , Lee, Victor , Gersh, Bernard J.

Mayo Clinic

Circulation | June 4, 2007 | Volume: 115 | Issue: 24 | Pages: 3050-3056

10.1161/circulationaha.106.644484 | PMID 17548732 Get It

Background— The long-term natural history of lone atrial fibrillation is unknown. Our objective was to determine the rate and predictors of progression from paroxysmal to permanent atrial fibrillation over 30 years and the long-term risk of heart failure, thromboembolism, and death compared with a control population. Methods and Results— A previously characterized Olmsted County, Minnesota, population with first episode of documented atrial fibrillation between 1950 and 1980 and no concomitant heart disease or hypertension was followed up long term. Of this unique cohort, 76 patients with paroxysmal (n=34), persistent (n=37), or permanent (n=5) lone atrial fibrillation at initial diagnosis met inclusion criteria (mean age at diagnosis, 44.2±11.7 years; male, 78%). Mean duration of follow-up was 25.2±9.5 years. Of 71 patients with paroxysmal or persistent atrial fibrillation, 22 had progression to permanent atrial fibrillation. Overall survival of the 76 patients with lone atrial fibrillation was 92% and 68% at 15 and 30 years, respectively, similar to 86% and 57% survival for the age- and sex-matched Minnesota population. Observed survival free of heart failure was slightly worse than expected ( P =0.051). Risk for stroke or transient ischemic attack was similar to the expected population risk during the initial 25 years of follow-up but increased thereafter ( P =0.004), although CIs were wide. All patients who had a cerebrovascular event had developed ≥1 risk factor for thromboembolism. Conclusions— Comorbidities significantly modulate progression and complications of atrial fibrillation. Age or development of hypertension increases thromboembolic risk.
Genetic Disruption of Kir6.2, the Pore-Forming Subunit of ATP-Sensitive K+ Channel, Predisposes to Catecholamine-Induced Ventricular Dysrhythmia
Liu, Xiaoke , Kane, Garvan C. , Alekseev, Alexey E., Hodgson, Denice M., O’Cochlain, Fearghas, Seino, Susumu , Yamada, Satsuki , Jahangir, Arshad , Miki, Takashi , Terzic, André , Liu, Xiaoke

Mayo Clinic

Diabetes | March 6, 2007 | Volume: 53 | Issue: suppl_3 | Pages: S165-S168

10.2337/diabetes.53.suppl_3.s165 | PMID 15561906 Get It

Metabolic-sensing ATP-sensitive K+ channels (KATP channels) adjust membrane excitability to match cellular energetic demand. In the heart, KATP channel activity has been linked to homeostatic shortening of the action potential under stress, yet the requirement of channel function in securing cardiac electrical stability is only partially understood. Here, upon catecholamine challenge, disruption of KATP channels, by genetic deletion of the pore-forming Kir6.2 subunit, produced defective cardiac action potential shortening, predisposing the myocardium to early afterdepolarizations. This deficit in repolarization reserve, demonstrated in Kir6.2-knockout hearts, translated into a high risk for induction of triggered activity and ventricular dysrhythmia. Thus, intact KATP channel function is mandatory for adequate repolarization under sympathetic stress providing electrical tolerance against triggered arrhythmia.
Cardioprotection: emerging pharmacotherapy
Gumina, Richard J. , Gross, Garrett J., Jahangir, Arshad , Terzic, André

Mayo Clinic

Expert Opinion on Pharmacotherapy | May 5, 2005 | Volume: 2 | Issue: 5 | Pages: 739-752

10.1517/14656566.2.5.739 | PMID 11336619 Get It

Syncope Evaluation in the Emergency Department Study (SEEDS)
Shen, Win K., Decker, Wyatt W., Smars, Peter A., Goyal, Deepi G. , Walker, A, Hodge, David O. , Trusty, Jane M., Brekke, Karen M., Brady, Peter A. , Munger, Thomas M. , Hammill, Stephen C., Frye, Robert L. , Jahangir, Arshad , Gersh, Bernard J.

Mayo Clinic

Circulation | November 9, 2004 | Volume: 110 | Issue: 24 | Pages: 3636-3645

10.1161/01.cir.0000149236.92822.07 | PMID 15536093 Get It

Background— The primary aim and central hypothesis of the study are that a designated syncope unit in the emergency department improves diagnostic yield and reduces hospital admission for patients with syncope who are at intermediate risk for an adverse cardiovascular outcome. Methods and Results— In this prospective, randomized, single-center study, patients were randomly allocated to 2 treatment arms: syncope unit evaluation and standard care. The 2 groups were compared with χ 2 test for independence of categorical variables. Wilcoxon rank sum test was used for continuous variables. Survival was estimated with the Kaplan-Meier method. One hundred three consecutive patients (53 women; mean age 64±17 years) entered the study. Fifty-one patients were randomized to the syncope unit. For the syncope unit and standard care patients, the presumptive diagnosis was established in 34 (67%) and 5 (10%) patients ( P <0.001), respectively, hospital admission was required for 22 (43%) and 51 (98%) patients ( P <0.001), and total patient-hospital days were reduced from 140 to 64. Actuarial survival was 97% and 90% ( P =0.30), and survival free from recurrent syncope was 88% and 89% ( P =0.72) at 2 years for the syncope unit and standard care groups, respectively. Conclusions— The novel syncope unit designed for this study significantly improved diagnostic yield in the emergency department and reduced hospital admission and total length of hospital stay without affecting recurrent syncope and all-cause mortality among intermediate-risk patients. Observations from the present study provide benchmark data for improving patient care and effectively utilizing healthcare resources.
Suppression of human tumor cell proliferation through mitochondrial targeting
Holmuhamedov, Ekhson , Bienengraeber, Martin, Holmuhamedova, Madina, Lewis, Lionel D. , Jahangir, Arshad , Terzic, André

Mayo Clinic

The FASEB Journal | July 28, 2002 | Volume: 16 | Issue: 9 | Pages: 1010-1016

10.1096/fj.01-0996com | PMID 12087062 Get It

ABSTRACT Intracellular calcium signaling plays a central role in cell proliferation. In leukemic cells, the calcium release‐activated calcium channels provide a major pathway for calcium entry (I CRAC ) perpetuating progression through the cell cycle. Although I CRAC is under mitochondrial regulation, targeting mitochondrial function has not been exploited to control malignant cell growth. The benzothiadiazine diazoxide, which depolarized respiration‐dependent mitochondrial membrane potential, reduced the rate of proliferation and arrested human acute leukemic T cells in the G0/G1 phase. Diazoxide did not alter cellular energetics, but rather inhibited the mitochondria‐controlled I CRAC and reduced calcium influx into tumor cells. The antiproliferative action of diazoxide was mimicked by removal of extracellular calcium or by the tyrphostin A9, an I CRAC inhibitor. Deletion of the mitochondrial genome, which encodes essential respiratory chain enzyme subunits, attenuated the inhibitory effect of diazoxide on I CRAC ‐mediated calcium influx and cell proliferation. Thus, manipulation of mitochondrial function and associated calcium signaling provides a basis for a novel anticancer strategy.—Holmuhamedov, E., Lewis, L., Bienengraeber, M., Holmuhamedova, M., Jahangir, A., Terzic, A. Suppression of human tumor cell proliferation through mitochondrial targeting. FASEB J. 16, 1010–1016 (2002)